Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Advisory panel conflicts

This article was originally published in The Gray Sheet

Executive Summary

FDA could have done more to mitigate conflicts-of-interest among its advisory committee members by expanding outreach efforts to retired experts, academics and others, the Government Accountability Office concludes in a 1report released Oct. 9. FDA uses several methods to recruit panel members, but sometimes cannot find appropriate experts with no financial interests in the product or issue being discussed and must grant a waiver. Congress requested in 2005 that GAO investigate FDA's recruitment and waiver policies (2"The Gray Sheet" Sept. 26, 2005, p. 7). GAO reviewed 83 committee meetings convened by FDA's device, drug and biologics centers in 2004 and 2006, and interviewed consumer advocacy and trade groups, current and former FDA staff, and former panel members. About 16% of panel members received at least one conflict-of-interest determination, GAO found. In Aug. 28 comments, FDA questioned GAO's main criticism and highlighted four guidance documents on advisory panel policies, finalized Aug. 4, which are beyond the scope of the report (3"The Gray Sheet" Aug. 11, 2008, p. 3)

You may also be interested in...



With Five Guidances, FDA Overhauls Its Advisory Committee Policies

FDA should hold voluntary advisory committee meetings only for matters that are of significant public interest or controversy, or that demand unique expertise, the agency's Office of Policy, Planning and Preparedness says in a 1draft guidance released Aug. 5

Roche Continues To Make The Case For Gantenerumab In Alzheimer’s Disease

The amyloid-targeting drug is years behind Biogen/Eisai’s aducanumab, but its subcutaneous administration and the GRADUATE studies’ design could give Roche’s gantenerumab an advantage.

Brinavess' US Review: EU Postmarket Data Unlikely To Save Troubled AFib Drug

Correvio's atrial fibrillation drug Brinavess will return to a US FDA advisory committee more than a decade after the agency first declined to approve the drug;  FDA still has a series of cardiovascular safety concerns related to the drug and is not convinced by data from the European experience.

UsernamePublicRestriction

Register

MT026657

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel